Current stock page

Financial Data

VRDN Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

VRDNViridian Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$30.87+$0.39 (+1.28%)

Latest quote

  • Momentum
    91
  • Value
    37
  • Quality
    41
  • Risk resilience
    46
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$25.75M$284K$141K$132K$70.57M$75K$72K$72K
Gross Profit$24.23M$284K$141K-$188K$70.57M$75K$72K$72K
Operating Income-$103.48M-$126.27M-$116.17M-$122.75M-$40.01M-$106.77M-$93.87M-$87.47M
Net Income-$101.21M-$127.12M-$104.9M-$120.36M-$34.6M-$100.74M-$86.91M-$79.73M
EPS-$0.81-$1.05-$0.9-$1.11-$0.34-$1.23-$0.87-$0.81
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$92.77M-$105.32M-$119.65M-$23.75M-$84.61M-$75.37M-$92.65M-$73.33M
Capital Expenditure-$370K-$1.31M-$23K-$240K-$127K-$42K-$86K-$114K
Free Cash Flow-$93.14M-$106.63M-$119.68M-$23.99M-$84.74M-$75.42M-$92.74M-$73.45M
Net Cash Provided By Operating Activities-$92.77M-$105.32M-$119.65M-$23.75M-$84.61M-$75.37M-$92.65M-$73.33M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.03B$1.1B$789.02M$899.42M$577.14M$582.32M$660.98M$742.4M
Total Debt$243.27M$242.88M$51.17M$50.69M$23.82M$21.34M$21.22M$21.1M
Cash And Cash Equivalents$172.86M$164.99M$176.35M$212.38M$169.65M$117.32M$116.22M$99.59M
Total Liabilities$447.97M$435.14M$153.01M$177.25M$74.17M$67.16M$56.51M$70.76M
Total Stockholders Equity$580.7M$662.1M$636.01M$722.17M$502.97M$515.17M$604.47M$671.64M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.583.673.013.463.972.721.621.72
P/S ratio133.07———————
Debt To Equity0.420.370.080.070.050.040.040.03
Free Cash Flow Yield-10.61%-13.80%-15.85%-11.07%-16.34%-22.06%-28.65%-20.18%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.583.673.013.463.972.721.621.72
P/S ratio133.07———————
Return On Equity-78.11%-58.45%-56.70%-47.44%-60.04%-66.79%-51.01%-40.19%
Debt To Equity0.420.370.080.070.050.040.040.03

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.98x
Pb6.03x
Revenue Growth Yoy-63.51%
EPS Growth Yoy-138.24%
Gross Margin92.98%
Operating Margin-1781.38%
ROE-69.76%
ROIC-48.85%
Debt To Equity0.42
FCF Yield-9.80%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$30.87
Volume1.2M
RSI (14)77.28
MACD2.61
MACD signal2.09
MACD histogram0.52
ADX (14)50.95
SMA (50)$22.75
SMA (200)$21.56
ATR (14)$1.35
Historical volatility (annualized)69.70%
Volume (20-day average)2.89M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score46/100
Beta1.14
Annual volatility71.98%
Max Drawdown-60.63%
Sharpe Ratio0.43
VaR (95%, 1-day)-4.19%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

VRDN Financial Data FAQ

What is Viridian Therapeutics, Inc.'s revenue?

Viridian Therapeutics, Inc.'s revenue is one of the core financial data points for VRDN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Viridian Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Viridian Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is VRDN's EPS?

VRDN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Viridian Therapeutics, Inc.'s net income?

Viridian Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Viridian Therapeutics, Inc. generate?

Free cash flow shows how much cash Viridian Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Viridian Therapeutics, Inc. have?

Cash and debt help frame VRDN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.